Navigation Links
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Date:4/28/2009

e antigenic challenge phase, no differences in the AE profile between the SparVax(TM) dose groups were noted.

Both vaccines were immunogenic following the 3-dose series with response rates of approximately 90%. There were no significant differences in either TNA or ELISA geometric mean titers (GMT) between the vaccine groups 14 days after the third vaccination. A strong immunologic memory response was observed at both 6 months and 12 months and no differences were seen between SparVax(TM) groups in terms of response rate or GMT measured by TNA.

The study concluded that SparVax(TM) was safe, well-tolerated and produced antibody responses comparable to the currently licensed product. The lower incidence of injection site reactions observed with SparVax(TM) may indicate that it is better tolerated than BioThrax(R), with good immunologic memory demonstrated after antigen exposure at 6 or 12 months.

"This is an important finding and supports the rationale for stockpiling a highly purified second generation anthrax vaccine utilizing modern vaccine technology as described in the March 2002 Institute of Medicine report, The Anthrax Vaccine: Is It Safe; Does it Work?," said Mr. Wright.

The SparVax(TM) Phase II clinical trial has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health.

Conference Call and Webcast Information

PharmAthene management will host a conference call to provide an update on the SparVax(TM) program on Wednesday, April 29, 2009, at 4:30 p.m., E.T. The dial-in number for U.S. callers is 1-866-788-0540 and for international callers is 857-350-1678. The participant passcode is 82129094.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. E.T. on April 29, 2009 until approximately 11:59 p.m. E.T. May 29
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Announces $5.5 Million Public Equity Offering
2. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
3. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
4. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
5. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
6. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
7. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
10. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
11. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... --   First published articles ... Elsevier , a world-leading provider of scientific, technical and ... launch of the latest title in the Current Opinion ... Science . Current Opinion ... platform to keep up-to-date with the expanding volume of information ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Continental ... patient populations into clinical trials at its mid-Atlantic ... , “Continental was created with the idea of ... a fundamental role in medical advances," said Continental's ... syphilis experiment to the immortal cell line of ...
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated ... company committed to the fostering and monetization of ... v. VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  ... No. 3:13-cv-03496-M, both in the United States District ... Texas . On November ...
(Date:11/22/2014)... November 21, 2014 Two new educational webinars ... comes next for ALS research and how the pharmaceutical industry ... the Ice Bucket Challenge: Where Does the ALS Money Go? ... 2 December 2014, Time: 1:30pm ET, Register to ... speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology at ...
Breaking Biology Technology:Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2
... introduced the world to tiny robots demonstrating soccer ... competition designed to advance microroboticsthe field devoted to ... dimensions are measured in micrometers (millionths of a ... Technology (NIST), in collaboration with IEEE, is inviting ...
... While other states jockeyed for position on Business ... its ranking as best in the Midwest and No. ... bioscience industry . , (Logo: ... bioscience ranking is in part due to updated estimates ...
... A faster tool for cell programming and a new way ... prizes of the 2009 Collegiate Inventors Competition, a program of ... Fund, the non-profit foundation of the global health care company ... Harris Wang, who invented a new way of cell ...
Cached Biology Technology:Is your microrobot up for the (NIST) challenge? 2Ohio Bioscience Industry Leads Midwest, Among Best in Nation as Investment Destination 2Winners Announced in 2009 Collegiate Inventors Competition(R) 2Winners Announced in 2009 Collegiate Inventors Competition(R) 3Winners Announced in 2009 Collegiate Inventors Competition(R) 4Winners Announced in 2009 Collegiate Inventors Competition(R) 5Winners Announced in 2009 Collegiate Inventors Competition(R) 6Winners Announced in 2009 Collegiate Inventors Competition(R) 7
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... suggests that a blood clot-dissolving medication that is administered ... may help to reduce the risk of amputation following ... issue of Archives of Surgery, one of the JAMA/Archives ... for the past 25 years, according to background information ...
... nanoparticle made in a laboratory at the University of ... device for treating glaucoma, an eye disease that can ... “The nanoparticle can safely get past the blood-brain barrier ... said Sudipta Seal, an engineering professor with appointments in ...
... of infections and other diseases of the brain is ... from reaching the brain. Grantees of the National Institute ... Institutes of Health, have now shown that a short ... strip of therapeutic material into the brain via intravenous ...
Cached Biology News:Clot-dissolving agent may be beneficial in treatment of severe frostbite 2UCF nanoparticle offers promise for treating glaucoma 2Blood-brain barrier breached by new therapeutic strategy 2
... be used to test the crossreactivity of ... that are commonly used as blocking reagents ... for 19 different protein preparations on a ... and species specificity, QC of purified antibodies, ...
... HydroFlex platform provides excellent performance, reliability ... 96-well format applications, including washing of ... and vacuum filtration-to-waste, such as for ... control features set new standards for ...
... Obtain Clean and Accurate Results Laser ... increase the sensitivity and accuracy of molecular ... cell types and multi-cellular structures isolated from ... approach to microdissection-developed in 1996 at the ...
...
Biology Products: